Research location

Kumamoto

Kumamoto, Japan

Published trials109
Site observations122
Linked trials published109
Page1 / 3
Advertisement

Research activity in Kumamoto

Kumamoto, Japan

CureCurrent currently publishes aggregate city-level research activity for this location: 109 trials and 122 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Kumamoto

109 linked trials · page 1 of 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)NCT07684144 · 2026-07-29 · 1 site observation
RECRUITING
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811 · 2025-10-02 · 1 site observation
RECRUITING
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 1 site observation
RECRUITING
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaNCT06882785 · 2025-06-10 · 1 site observation
RECRUITING
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 · 2025-02-27 · 1 site observation
RECRUITING
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT04928846 · 2022-03-25 · 1 site observation
RECRUITING
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686 · 2025-12-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyNCT07226765 · 2025-11-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878 · 2025-03-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaNCT06894212 · 2025-02-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)NCT06635824 · 2024-11-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)NCT06660173 · 2024-11-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerNCT06311721 · 2024-09-09 · 1 site observation
ACTIVE_NOT_RECRUITING
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)NCT05973773 · 2023-12-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Special Drug Use Surveillance of Entresto Tablets (Hypertension)NCT05976230 · 2023-09-04 · 1 site observation
COMPLETED
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT05814627 · 2023-06-15 · 1 site observation
COMPLETED
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaNCT05368558 · 2022-08-18 · 1 site observation
TERMINATED
A Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO)NCT05326230 · 2022-07-01 · 2 site observations
ACTIVE_NOT_RECRUITING
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe AsthmaNCT05421598 · 2022-06-30 · 1 site observation
COMPLETED
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in JapanNCT05359081 · 2022-05-16 · 2 site observations
TERMINATED
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).NCT05227209 · 2022-03-17 · 1 site observation
TERMINATED
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsNCT05215340 · 2022-03-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.NCT05169710 · 2021-12-21 · 1 site observation
TERMINATED
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)NCT04888585 · 2021-06-23 · 1 site observation
TERMINATED
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)NCT04720157 · 2021-06-09 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus LetrozoleNCT04735367 · 2021-02-03 · 1 site observation
COMPLETED
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast CancerNCT04524000 · 2021-01-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS PatientsNCT04593927 · 2020-10-28 · 1 site observation
COMPLETED
Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ TabletsNCT04340115 · 2020-04-24 · 3 site observations
COMPLETED
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerNCT04100018 · 2020-02-06 · 1 site observation
COMPLETED
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsNCT04129502 · 2020-01-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)NCT03725059 · 2018-12-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With ObesityNCT03320941 · 2017-12-07 · 2 site observations
COMPLETED
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)NCT03071692 · 2017-03-23 · 1 site observation
TERMINATED
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyNCT02864251 · 2017-03-17 · 1 site observation
COMPLETED
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329 · 2017-01-06 · 1 site observation
COMPLETED
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung CancerNCT02810457 · 2016-09-07 · 1 site observation
COMPLETED
Long-term Safety of Tafamidis in Subjects With Transthyretin CardiomyopathyNCT02791230 · 2016-06-13 · 1 site observation
COMPLETED
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)NCT02706951 · 2016-03-23 · 2 site observations
COMPLETED
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDsNCT02720523 · 2016-03-22 · 1 site observation
COMPLETED
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken MethotrexateNCT02706873 · 2016-02-23 · 3 site observations
COMPLETED
Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid ArthritisNCT02638948 · 2016-02-16 · 1 site observation
COMPLETED
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast CancerNCT02514681 · 2015-08-01 · 1 site observation
COMPLETED
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection FractionNCT02468232 · 2015-06-15 · 1 site observation
COMPLETED
Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)NCT02379091 · 2014-12-17 · 1 site observation
COMPLETED
A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and MicroalbuminuriaNCT02332824 · 2014-10-16 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHFNCT02007720 · 2014-03-12 · 1 site observation
TERMINATED
A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)NCT01989676 · 2014-02-24 · 1 site observation
COMPLETED
Safety and Efficacy of Tafamidis in Patients With Transthyretin CardiomyopathyNCT01994889 · 2013-12-09 · 1 site observation
COMPLETED
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.